Reven Pharmaceuticals

Reven hits back, opposing SEC’s motion for injunctive relief.

https://reven.com/revens-response-peter-lange-michael-volk-brian-denomme-james-ervin-leah-schaatt-lee-ann-frost/

Reven among companies expected to boost hypoxia market

Hypoxia Market Growing Significantly, Assesses DelveInsight | Teclison Ltd., Merck, Eli Lilly and Company, Reven Pharmaceuticals, Biogen Expected to Boost Hypoxia Market The dynamics of the hypoxia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental...

The Reven team is aware of the recent SEC action against the company and some of its executives. Reven denies the allegations and is working through counsel to respond to them.

REVEN ANNOUNCES A STRATEGIC LICENSING PARTNERSHIP WITH ENLIGHTENED NUTRACEUTICAL SOLUTIONS, LLC (ENS)

https://reven.com/press-release/reven-announces-a-strategic-licensing-partnership-with-enlightened-nutraceutical-solutions-llc/

REVEN ANNOUNCES A STRATEGIC LICENSING PARTNERSHIP WITH ENLIGHTENED NUTRACEUTICAL SOLUTIONS, LLC (ENS) TO ALLOW ENS TO LEVERAGE REVEN’S CLINICAL RESEARCH IN ANTI-INFLAMMATORY AND ANTIOXIDANT MEDICINE TOWARD ITS EFFORTS TO DEVELOP NEW PROPRIETORY... Reven today announced that it has licensed intellectual property, technology and knowledge pertaining to multiple owned patents supported by a decade of pre-clinical and clinical research in anti-inflammatory effects of bio-similar nutrients to ENS

We have posted our 2021 Annual Year End Recap to our website and Carta.

https://reven.com/press-release/2021-annual-year-end-recap/

Reven 2021 Annual Year End Recap - Reven Pharmaceuticals Dear Shareholders, 2021 is now behind us and we, at Reven, continue to look forward. Despite the pandemic challenges that impacted all aspects of normal business operations, the Reven management team continues to prepare the company for the commercialization of its flagship drug, RJX.

Reven Holdings Announces the Publication of a Peer-reviewed Article in the Prestigious Medical Journal Frontiers in Oncology

https://www.businesswire.com/news/home/20211105005307/en/Reven-Holdings-Announces-the-Publication-of-a-Peer-reviewed-Article-in-the-Prestigious-Medical-Journal-Frontiers-in-Oncology

Reven Holdings Announces the Publication of a Peer-reviewed Article in the Prestigious Medical Journal Frontiers in Oncology Exciting Medical and Scientific Progress Reported for Reven Holdings’ COVID-19 Drug Candidate

Reven Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211022005108%2Fen%2FReven-Holdings-Announces-First-Patient-Dosed-in-Double-blind-Randomized-Multi-institutional-Phase-2-Clinical-Trial-Evaluating-Its-Lead-Anti-sepsis-Drug-Candidate-RJX-in-Hospitalized-High-risk-COVID-19-Patients&data=04%7C01%7Cdane.baruzzini%40reven.com%7C6e91e72ed0d7478ce51108d9956d4e07%7C06cec2c4941d45d3870884725cafd7d3%7C0%7C0%7C637705118960988073%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=4ASeFNpXYu3dtP3%2FLmMK1OwtERBVtQTbNyMl%2BItkRH8%3D&reserved=0

Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients October 22, 2021 08:30 AM Eastern Daylight Time WESTMINSTER, Colo.--(BUSINESS WIRE)--Rev...

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

https://www.businesswire.com/news/home/20210924005085/en/Reven-Holdings-Announces-Successful-Completion-of-the-First-Part-of-RPI015-Clinical-Trial-Evaluating-Its-Lead-Anti-sepsis-Drug-Candidate-RJX%C2%A0in-Hospitalized-High-risk-COVID-19-Patients

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients REVEN SUCCESSFULLY COMPLETES PART 1 OF THE RANDOMIZED COVID-19 STUDY EVALUATING ITS LEAD ANTI-SEPSIS DRUG CANDIDATE RJX

Reven's Co-Founder Michael Volk Appears on Cheddar News

https://www.businesswire.com/news/home/20210709005449/en/Reven%E2%80%99s-Co-Founder-Michael-Volk-Appears-on-Cheddar-News

Reven’s Co-Founder Michael Volk Appears on Cheddar News Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of

Yesterday, Reven's Co-Founder, Michael Volk sat down with Cheddar News to talk about Reven Pharmaceuticals, RJX, and our clinical trials.



https://cheddar.com/media/reven-pharmaceuticals-has-raised-90-million-without-vc-funding

Reven Pharmaceuticals Has Raised $90 Million Without VC Funding Reven Pharmaceuticals has raised nearly $90 million dollars without venture capital funding. It's flagship product targets multiple bodily systems to keep everything operating in harmony. Michael Volk, Co-Founder, Chief Strategy Officer of Reven Pharmaceuticals, joined Cheddar to discuss.

Reven Pharmaceuticals Reports a Promising Second Generation Formulation of Its Lead Anti-sepsis Drug Candidate Rejuveinix (RJX)

https://www.businesswire.com/news/home/20210618005090/en/Reven-Pharmaceuticals-Reports-a-Promising-Second-Generation-Formulation-of-Its-Lead-Anti-sepsis-Drug-Candidate-Rejuveinix-RJX

Reven Pharmaceuticals Reports a Promising Second Generation Formulation of Its Lead Anti-sepsis Drug Candidate Rejuveinix (RJX) Reven Team publishes a new peer-reviewed paper on a novel formulation of its proprietary anti-sepsis drug candidate RJX.

Reven Announces Daniel Hoffman As Chief Operating Officer

https://www.businesswire.com/news/home/20210607005159/en/Reven-Announces-New-Chief-Operating-Officer

Reven Announces New Chief Operating Officer Reven announces new COO

Bio World discusses Reven’s Clinicial Trial

https://www.bioworld.com/articles/506539-new-covid-19-therapy-trials-ramp-up-as-weekly-cases-surpass-previous-peaks

New COVID-19 therapy trials ramp up as weekly cases surpass previous peaks Urgency to meet the world's worsening load of COVID-19 cases appeared unflagging Thursday, with four new trials kicking off to evaluate treatments aimed at keeping people from progressing to worsened disease and reports on two new variant-focused efforts yielding signs of preclinical promise.

Reven Announces First Patient Dosed in RPI015 Clinical Trial Evaluating RJX for High-Risk COVID-19 Patients

https://www.biospace.com/article/releases/reven-holdings-announces-first-patient-dosed-in-rpi015-clinical-trial-evaluating-rjx-for-high-risk-covid-19/

Reven Holdings Announces First Patient Dosed in RPI015 Clinical Trial Evaluating RJX for High-risk COVID-19 | BioSpace Reven Holdings Announces First Patient Dosed in RPI015 Clinical Trial Evaluating RJX for High-risk COVID-19 - read this article along with other careers information, tips and advice on BioSpace

We are proud to announce the launch of our Translational Oncology Program!

https://www.businesswire.com/news/home/20210423005151/en/Reven-Holdings-Announces-the-Launch-of-Its-Translational-Oncology-Program-Targeting-Tumor-Microenvironment-to-Improve-Treatment-Outcomes-in-Cancer

Reven Holdings Announces the Launch of Its Translational Oncology Program: Targeting Tumor Microenvironment to Improve Treatment Outcomes in Cancer Reven Holdings Announces the Launch of Its Translational Oncology Program: Targeting Tumor Microenvironment to Improve Treatment Outcomes in Cancer

Attention Investors!

We have posted our 2020 year end update on our website.

https://reven.com/press-release/reven-2020ye-shareholder-update/

Reven 2020YE Shareholder Update - Reven Pharmaceuticals We are happy to share the progress of Reven Holdings, Inc. (“Reven”) for the 2020 year. Despite an unprecedented global pandemic, 2020 was another year filled with major milestones for the company

Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure

Frontiers in Pharmacology article detailing Reven's favorable clinical safety profile in human subjects and potent preclinical activity.

https://www.frontiersin.org/articles/10.3389/fphar.2020.594321/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Pharmacology&id=594321

frontiersin.org Background: New treatment platforms that can prevent acute respiratory distress syndrome (ARDS) or reduce its mortality rate in high-risk coronavirus disease 2019 (COVID-19) patients, such as those with an underlying cancer, are urgently needed. Rejuveinix (RJX) is an intravenous formulation of anti...

Reven Pharmaceuticals Reports Positive Results Regarding the Clinical Safety and Preclinical Efficacy of its COVID-19 Drug Candidate Rejuveinix (RJX) - Reven Pharmaceuticals

Reven Pharmaceuticals Reports Positive Results Regarding the Clinical Safety and Preclinical Efficacy of its COVID-19 Drug Candidate Rejuveinix (RJX)

https://reven.com/press-release/reven-pharmaceuticals-reports-positive-results-regarding-the-clinical-safety-and-preclinical-efficacy-of-its-covid-19-drug-candidate-rejuveinix-rjx/

reven.com Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology. In this new publication, the Reven Pharmaceuticals team reports positive results regarding the clinical safety and preclinical efficacy

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

https://www.yahoo.com/now/reven-pharmaceuticals-reports-importance-micronutrients-183100915.html

yahoo.com REVEN PHARMACEUTICALS REPORTS ON THE IMPORTANCE OF MICRONUTRIENTS AND VITAMINS FOR COVID-19

Reven Pharmaceuticals Wins FDA Approval of Its IND Application for Treatment of COVID-19 With Rejuveinix (RJX)

Reven Wins FDA Approval of Its IND Application for Treatment of COVID-19 with Rejuveinix (RJX)

https://www.businesswire.com/news/home/20201022005456/en/Reven-Pharmaceuticals-Wins-FDA-Approval-of-Its-IND-Application-for-Treatment-of-COVID-19-With-Rejuveinix-RJX

businesswire.com REVEN PHARMACEUTICALS WINS FDA APPROVAL OF ITS IND APPLICATION FOR TREATMENT OF COVID-19 WITH REJUVEINIX (RJX)

Reven Strengthens its Clinical Team with Three New Members - Reven Pharmaceuticals

Reven Strengthens its Clinical Team with Three New Members

https://reven.com/press-release/reven-strengthens-its-clinical-team-with-three-new-members/

reven.com Reven today announced that three new members with extensive experience and knowledge in clinical research and quality assurance have joined its multi-disciplinary team to work on the COVID-19 clinical project

Reven Selects‌ E-Clinical Services‌ Provider‌ DSG for Clinical Data Management Services - Reven Pharmaceuticals

Reven Selects‌ E-Clinical Services‌ Provider‌ DSG for Clinical Data Management Services

https://reven.com/press-release/reven-selects-e-clinical-services-provider-dsg-for-clinical-data-management-services/

reven.com Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19.

Reven Selects APCER Life Sciences as Its Service Provider in Pharmacovigilance, Safety Monitoring, Quality Assurance and Regulatory Affairs for Its Upcoming COVID-19 Clinical Trial

Reven has selected APCER Life Sciences as its preferred vendor to provide pharmacovigilance (PVG), safety monitoring, quality assurance and regulatory affairs services for its COVID-19 clinical project.

https://www.businesswire.com/news/home/20200921005248/en/Reven-Selects-APCER-Life-Sciences-as-Its-Service-Provider-in-Pharmacovigilance-Safety-Monitoring-Quality-Assurance-and-Regulatory-Affairs-for-Its-Upcoming-COVID-19-Clinical-Trial

businesswire.com Reven Selects Its Service Provider in Pharmacovigilance, Safety Monitoring, QA, and Regulatory Affairs for Its Upcoming COVID-19 Clinical Trial

US Patent and Trademark Office Allows Reven’s Patent Application to Issue as a New Patent

https://www.businesswire.com/news/home/20200917005284/en/US-Patent-and-Trademark-Office-Allows-Reven%E2%80%99s-Patent-Application-to-Issue-as-a-New-Patent

businesswire.com Reven received a formal Notice of Allowance from the US Patent and Trademark Office regarding its patent application for RJX

US Patent and Trademark Office Allows Reven’s Patent Application to Issue as a New Patent - Reven Pharmaceuticals

US Patent and Trademark Office Allows Reven’s Patent Application to Issue as a New Patent

https://reven.com/press-release/us-patent-and-trademark-office-allows-revens-patent-application-to-issue-as-a-new-patent/

reven.com Reven today announced that it received a formal Notice of Allowance from the US Patent and Trademark Office regarding its patent application entitled: “Compositions and Methods for the Prevention and Treatment of Cardiovascular Disease”

Reven’s Patented, First-in-Class Anti-inflammatory Treatment Platform for Sepsis on Track for Clinical Testing in COVID-19 Patients

Reven’s Patented, First-in-Class Anti-inflammatory Treatment Platform for Sepsis on Track for Clinical Testing in COVID-19 Patients

https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20200914005290%2Fen%2FReven%25E2%2580%2599s-Patented-First-in-Class-Anti-inflammatory-Treatment-Platform-for-Sepsis-on-Track-for-Clinical-Testing-in-COVID-19-Patients&data=02%7C01%7Cdane.baruzzini%40reven.com%7C6a41a6d4af8b4a5e539408d858bbb4a2%7C06cec2c4941d45d3870884725cafd7d3%7C0%7C0%7C637356910504495730&sdata=8qTl%2BjVGwVs1lnlxqs%2B2IyiLwWSNjSMO9Rre0Jl6izA%3D&reserved=0

businesswire.com Reven’s Patented, First-in-Class Anti-inflammatory Treatment Platform for Sepsis Is on Track for Clinical Testing in COVID-19 Patients

According to the CDC, adherence to the community’s and company’s face-covering policy likely mitigated spread of SARS-CoV-2.

In a patient with peripheral arterial disease, exercise has been shown to improve vascular function, inflammation, and oxidative stress.



SOURCE: Novakovic M, Jug B, Lenasi H. Clinical impact exercise patients with peripheral arterial disease

Acid can be harmful to the body. One might consider adopting an alkaline diet to support a healthier pH in the blood stream.

Many of us might not know what acids and bases are or what they do.